Mercans Named Global Leader in Payroll Technology for the Second Consecutive Year - ISG Provider Lens™ 2024
For the second consecutive year, ISG, an independent research firm, has named Mercans a Leader in its Global Managed Payroll Services (Multi-Country) ISG Provider Lens™ 2024 report.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241008882905/en/
Mercans Named Global Leader in Payroll Technology for the Second Consecutive Year - ISG Provider Lens™ 2024 (Photo: AETOSWire)
In this annual assessment, out of 26 payroll solutions and services providers evaluated, Mercans stood out as an industry leader for its G2N Nova platform which uses cutting-edge artificial intelligence (AI) and machine learning (ML) to deliver anonymous, accurate payroll services to companies worldwide. The platform’s ability to automate workflows and eliminate human intervention ensures that payroll operations are both secure and error-free, further solidifying Mercans’ position as an industry leader.
ISG Analyst Applauds Mercans’ Digital Transformation in Payroll
ISG commended Mercans for leading digital transformation in global payroll, specifically highlighting its groundbreaking G2N Nova platform. G2N Nova is the only stateless global payroll application capable of performing gross-to-net calculations for over 100 countries within seconds—without storing any employee data. This disruptive innovation is helping multinationals fully digitalize their payroll operations, enabling faster, more secure processing.
The platform’s unique ability to deliver an autonomous, touchless payroll experience drastically reduces both processing times and costs. G2N Nova has disrupted traditional payroll models by eliminating the need for in-country subcontractors and 3rd party software, empowering companies to consolidate their global payroll operations in a single system.
Anonymous Payroll, AI-Powered Accuracy and Global Reporting
Mercans’ G2N Nova platform uses AI and ML to automate payroll processes, enhancing accuracy and eliminating human intervention. Payroll calculations are conducted without accessing PII, ensuring compliance with global privacy regulations. Its audit system flags suspicious transactions for added security.
G2N Nova offers advanced analytics and global reporting, consolidating payroll data across 100+ countries. The platform offers a unified payroll experience, supported by Mercans’ proprietary technology and local experts, without relying on third-party providers or subcontractors.
Flexible Operating Models for Diverse Business Needs
Mercans provides a flexible range of payroll service models, including Software as a Service (SaaS), Managed Services, and Business Process Outsourcing (BPO). These options allow businesses to adapt their payroll solutions to their needs, with the ability to transition between models seamlessly. G2N Nova’s horizontal architecture powers SaaS and managed payroll services for thousands of companies globally, consolidating payroll processing and reporting on a single platform.
Rachel Anderson, Lead Analyst at ISG, commends Mercans, stating, “Mercans is scaling rapidly with its native gross-to-net solution. The payroll is processed in its own payroll engine in 160 countries, without any in-country partners.”
Read the full ISG Provider Lens™ 2024 report here.
About Mercans
Mercans is a global leader in payroll technology. Mercans’ revolutionary global payroll engine G2N Nova enables enterprise businesses & HCM providers to perform gross to-net calculations across 100+ legislation. To learn more about this innovative platform, visit www.mercans.com
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20241008882905/en/
Contacts
Mohsin Khan -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.c
om%2Fin%2Fmohsin000%2F&esheet=54133020&newsitemid=20241008882905&lan=en-US&ancho
r=Mohsin+Khan&index=5&md5=8d5612698dc936c91cea4ce9ae2c6cc4
hello@mercans.com
Berkeley Square House, 2nd Floor, Berkeley Square, London, UK.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 22:46:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 22:35:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 21:32:00 EET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 14:00:00 EET | Press release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 14:00:00 EET | Press release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom